SCHEMBL25251119

SCHEMBL25251119

CS(=O)(=O)c1ccc(CC2CC3(C2)CN(C(=O)O)C3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR5 P51681 1/20 0.43
▸ GPR119 Q8TDV5 5/20 0.40
▸ LMNA P02545 1/20 0.38
▸ CCR3 P51677 1/20 0.38
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ DUSP3 P51452 1/20 0.37
▸ PTPN5 P54829 1/20 0.37
▸ PTPN11 Q06124 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ RORC P51449 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25294377 0.85 GRM2 (0.41) CCR5ALDH1A1L3MBTL1
SCHEMBL25248238 0.83 GPR119 (0.57) GPR119
SCHEMBL25260188 0.82 GPR119 (0.33) CCR5GPR119CCR3MEN1KMT2A
SCHEMBL30699883 0.78 CCR5 (0.40) CCR5GPR119LMNACCR3CA12
SCHEMBL30409381 0.78 MGLL (0.40) CCR5GPR119CCR3RORC
SCHEMBL25326672 0.78 CCR5 (0.38) CCR5GPR119CCR3RORC
SCHEMBL30409404 0.77 MGLL (0.42) —
SCHEMBL25328128 0.77 GPBAR1 (0.37) CCR5GPR119CCR3RORC
SCHEMBL25300786 0.76 CCR5 (0.40) CCR5GPR119CCR3SMN1; SMN2
SCHEMBL25299011 0.75 LMNA (0.54) LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981661-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-05-14 — — US disclosed
EP-4208456-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2023-07-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981661-B2 Heterocyclic compounds CBR3, BRIX1, CCNY CCR5 309/4885GPR119 2316/4885LMNA 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback